In a report released today, Neal Gilmer from Haywood reiterated a Buy rating on Cresco Labs, with a price target of C$2.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neal Gilmer has given his Buy rating due to a combination of factors including Cresco Labs’ financial performance and strategic initiatives. The company’s Q3 2025 results showed a slight increase in EBITDA, driven by better-than-expected gross margins, which indicates effective cost management and operational efficiency. Additionally, Cresco Labs has successfully strengthened its balance sheet by refinancing its senior credit facility and generating $6 million in operating cash flow, which underscores its financial stability.
Furthermore, Cresco Labs’ strategic decision to exit the California market allows it to concentrate on its core markets, enhancing its focus on margin expansion. The company’s plans to enter the international market, specifically Germany, with a branded flower launch, demonstrate its potential for growth and diversification. These factors collectively contribute to Neal Gilmer’s confidence in Cresco Labs’ future prospects, justifying the Buy rating.
Gilmer covers the Healthcare sector, focusing on stocks such as Green Thumb Industries, Trulieve Cannabis, and Cresco Labs. According to TipRanks, Gilmer has an average return of 1.6% and a 44.60% success rate on recommended stocks.